DBV Technologies S.A. (NASDAQ:DBVT) has received a consensus recommendation of “Buy” from the eleven analysts that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $47.80.

DBVT has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of DBV Technologies in a report on Thursday, July 6th. BidaskClub upgraded DBV Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. Deutsche Bank AG initiated coverage on DBV Technologies in a report on Friday, June 23rd. They issued a “buy” rating and a $46.00 price target on the stock. Jefferies Group LLC reiterated a “buy” rating and set a $47.00 target price on shares of DBV Technologies in a report on Thursday, June 1st. Finally, Zacks Investment Research upgraded DBV Technologies from a “sell” rating to a “hold” rating and set a $49.00 target price on the stock in a report on Tuesday, August 1st.

TRADEMARK VIOLATION NOTICE: “Brokerages Set DBV Technologies S.A. (NASDAQ:DBVT) PT at $47.80” was published by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/07/brokerages-set-dbv-technologies-s-a-nasdaqdbvt-pt-at-47-80.html.

A number of large investors have recently made changes to their positions in the stock. Jennison Associates LLC boosted its stake in shares of DBV Technologies by 86.4% in the second quarter. Jennison Associates LLC now owns 1,002,067 shares of the company’s stock worth $35,784,000 after buying an additional 464,341 shares during the period. Alliancebernstein L.P. boosted its stake in shares of DBV Technologies by 21.1% in the first quarter. Alliancebernstein L.P. now owns 996,535 shares of the company’s stock worth $35,098,000 after buying an additional 173,798 shares during the period. Morgan Stanley boosted its stake in shares of DBV Technologies by 89.9% in the first quarter. Morgan Stanley now owns 249,988 shares of the company’s stock worth $8,805,000 after buying an additional 118,317 shares during the period. Marshall Wace North America L.P. bought a new stake in shares of DBV Technologies during the first quarter worth approximately $3,566,000. Finally, MARSHALL WACE ASIA Ltd bought a new stake in shares of DBV Technologies during the first quarter worth approximately $3,566,000. Hedge funds and other institutional investors own 47.98% of the company’s stock.

Shares of DBV Technologies (DBVT) opened at 45.53 on Friday. DBV Technologies has a 52 week low of $31.87 and a 52 week high of $45.70. The stock has a 50 day moving average price of $38.47 and a 200-day moving average price of $35.58. The firm’s market capitalization is $2.09 billion.

About DBV Technologies

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.